President Trump officially launched TrumpRx on February 5, touting it as a game-changer for prescription drug costs. The reality, however, is that health policy experts believe only a limited number of Americans will actually benefit from this plan, while millions could end up paying more without comparison shopping. Must Read According to a White House press release, the TrumpRx.gov website features at least 40 brand-name medications with discounted prices from five pharmaceutical companies (1). And w ...

分组1 - Stellantis expects a $26 billion hit from a business overhaul, leading to a more than 25% drop in its U.S.-listed shares [1] - The company's stock has already decreased over 12% at the start of 2026 [1] 分组2 - Bob's Discount Furniture had its IPO priced at $17 per share, valuing the company at $2.22 billion [8] - The IPO comes at a time when traditional IPOs raised $33.6 billion in 2025, marking the best year since 2021 [8] 分组3 - Peloton shares fell more than 25% due to weak quarterly earnings and demand [9] - Estée Lauder's stock dropped over 19% after announcing a $100 million hit to full-year profitability due to tariffs [9]

来源：金十数据整理（2026-02-06） 1． 宣布高市早苗将于3月19日访美——特朗普周四宣布，日本首相高市早苗将于3月19日访问白宫。 2． 等待美伊谈判最新消息——白宫称特朗普更倾向于通过外交途径解决紧张局势，并将在会谈结束后 听取其代表的简报。特朗普高级外交特使威特科夫和他的女婿库什纳代表美国参加会谈。 3． 美政府将取消约5万名联邦雇员就业保障——当地时间2月5日，美国政府将取消5万名联邦雇员的就 业保障。美政府宣布对联邦雇员的分类方式进行全面改革，使总统更容易解雇非政治性公务员。 5． 支持匈牙利总理欧尔班连任——特朗普在匈牙利4月举行关键选举前夕，公开支持匈牙利总理欧尔 班。他在社交媒体上称"完全支持他连任匈牙利总理"。欧尔班的右翼政党青民盟在民意调查中落后于中 右翼政党蒂萨党。 6． 美国应该与俄罗斯谈判一项"新的、改进的、现代化的"核条约——特朗普表示，美国应该与俄罗斯 谈判一项"新的、改进的、现代化的"核条约，而不是同意延长《新削减战略武器条约》 。 7． 保留迪戈加西亚岛"军事安全"基地的权利——特朗普周四表示，他与英国首相斯塔默就迪戈加西亚 岛的未来进行了"非常富有成效的讨论"。特朗 ...

President Donald Trump plans to unveil a website allowing people to directly purchase prescription drugs, part of his push to address Americans’ concerns about affordability.The president launched the site — branded as TrumpRx — at the White House alongside Centers for Medicare and Medicaid Services Administrator Mehmet Oz and government design chief Joe Gebbia, White House Press Secretary Karoline Leavitt posted on X. TONIGHT AT 7PM: President Trump, Dr. Oz, and National Design Studio Director Joe Gebbia w ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is a key integration partner for pharmaceutical companies offering discounted cash prices on TrumpRx. TrumpRx is a website that lists discounted cash prices from pharmaceutical manufacturers. TrumpRx does not sell or dispense drugs. Instead, TrumpRx facilitates consumer access to the selected discount, and then the underlying partner platform executes. ...

Core Viewpoint - Pfizer (PFE.US) is set to release its Q3 earnings report on November 4, with expectations of a significant decline in both earnings per share and revenue, reflecting market concerns about the company's ability to adapt to post-pandemic demand normalization [1] Financial Performance - Expected earnings per share (EPS) for Q3 is $0.64, a year-over-year decrease of 39.6% - Projected revenue is $16.52 billion, down 6.7% year-over-year - Pfizer has exceeded EPS expectations for eight consecutive quarters, but only 63% of the time for revenue [1] Analyst Sentiment - Analysts have become increasingly cautious, with EPS expectations being downgraded 15 times and revenue expectations 10 times in the past three months - This trend indicates growing concerns regarding Pfizer's performance in the current market environment [1] Stock Performance - Year-to-date, Pfizer's stock has declined over 7%, underperforming the market, which has risen by 16% - Recent positive developments and a temporary suspension of drug import tariffs by the Trump administration may lead to a potential rebound in Pfizer's stock price [1] Strategic Initiatives - In late September, Pfizer committed to providing discounts of up to 85% on four prescription drugs through the TrumpRx pricing platform - The company also pledged to invest $70 billion in drug production and R&D in exchange for a three-year tariff exemption [1] Upcoming Developments - The upcoming earnings report is expected to shed light on Pfizer's progress in cancer treatment and the tangible impact of tariff policies on profitability - The ongoing acquisition bid for Metsera (MTSR.US) by Novo Nordisk, which raised its offer to $9 billion, will also be a focal point [2]

Core Insights - Mark Cuban's CostPlus Drugs launched in 2022 aims to disrupt the prescription drug industry by providing a digital marketplace that reduces costs through direct purchasing [1] - President Donald Trump announced a competing platform, TrumpRx, set to launch in early 2026, which will also focus on lowering prescription drug prices [1][2] Pricing Models - Both CostPlus Drugs and TrumpRx aim to eliminate middlemen in the prescription drug supply chain to lower prices [3] - CostPlus Drugs adds a 15% markup to the direct purchase cost of over 2,300 medications, along with a $5 pharmacy charge and a $5 shipping fee [8] - TrumpRx will direct users to participating drug manufacturers' websites for brand-name prescriptions at reduced prices, but it currently has limited partnerships [4][8] Drug Selection and Coverage - As of October 1, Pfizer is the only pharmaceutical company that has agreed to terms for TrumpRx, limiting the selection to 313 drugs without generics or insurance acceptance [4] - In contrast, CostPlus Drugs accepts coverage from over two dozen insurance providers and offers thousands of generic prescriptions at significantly reduced prices [5] Cost Comparisons - The White House showcased potential savings from TrumpRx using three common Pfizer prescriptions, but these do not have generic alternatives available on CostPlus Drugs [6]

Core Insights - Retail pharmacies and prescription drug savings site GoodRx are in discussions with the Trump administration regarding potential collaboration with the TrumpRx website, indicating a possible expansion of services beyond initial offerings [1] Group 1 - GoodRx is exploring opportunities to join the TrumpRx initiative, which may enhance its visibility and service offerings in the prescription drug market [1] - The discussions suggest a strategic move to align with government efforts to improve access to affordable medications [1]

Healthcare Industry News - A new drug-buying site called "TrumpRx" has been announced for Americans [1] - The site aims to help Americans save money on prescription drugs [1]

Healthcare Initiatives - The pharmaceutical industry is responding to President Trump's announcement of a new drug-buying site called "TrumpRx" for Americans [1] - The initiative aims to potentially reduce drug costs for consumers [1]